Citadel Advisors’s CollPlant Biotechnologies CLGN Stock Holding History

Citadel Advisors’s Portfolio CLGN Stock Details CLGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18.7K	Buy	5,370 +2,153	+67%	+$8.29K	﹤0.01%	13418
2026 Q1	$17.2K	Buy	+3,217	New	+$32.5K	﹤0.01%	12700
2024 Q2	–	Sell	-1,319	Closed	-$71.1K	–	14362
2024 Q1	$71.1K	Buy	1,319 +646	+96%	+$34.9K	﹤0.01%	11799
2023 Q4	$43K	Buy	+673	New	+$36.8K	﹤0.01%	11940
2021 Q3	–	Sell	-1,303	Closed	-$276K	–	13859
2021 Q2	$276K	Buy	+1,303	New	+$208K	﹤0.01%	11461
2021 Q1	–	Sell	-1,194	Closed	-$126K	–	13203
2020 Q4	$126K	Buy	1,194 +97	+9%	+$7.84K	﹤0.01%	10061
2020 Q3	$88K	Buy	+1,097	New	+$98.7K	﹤0.01%	9345
2019 Q3	–	Sell	-1,112	Closed	-$44K	–	9206
2019 Q2	$44K	Buy	+1,112	New	+$58.4K	﹤0.01%	8761
2018 Q4	–	Sell	-1,389	Closed	-$72K	–	9155
2018 Q3	$72K	Buy	+1,389	New	+$76.6K	﹤0.01%	8697

Other funds holding CLGN

Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $838M AUM 14.24% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Pathstone Holdings Englewood, New Jersey $34.3B AUM 27.35% 1-Year Est. Return

LWMI

Legacy Wealth Management (Idaho) Boise, Idaho $243M AUM 8.27% 1-Year Est. Return

WPC

Waters Parkerson & Co New Orleans, Louisiana $2.03B AUM 17.65% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citadel Advisors's CLGN Position: Q2 2026 in Review

Citadel Advisors increased its CollPlant Biotechnologies (CLGN) stake by 67% in Q2 2026, buying an estimated $8.29K and bringing the position to 5,370 shares worth $18.7K. The position accounts for ﹤0.01% of the portfolio, ranked #13418.

Citadel Advisors first reported a position in CLGN in Q3 2018 and has held it in 9 quarters since. The position peaked at $276K in Q2 2021. 15 funds tracked by Wall St. Rank hold CLGN as of Q2 2026.

Citadel Advisors held 5,370 shares of CollPlant Biotechnologies worth $18.7K as of Q2 2026.
Citadel Advisors bought 2,153 CollPlant Biotechnologies shares in Q2 2026, an estimated $8.29K.
CollPlant Biotechnologies made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13418 holding.
Citadel Advisors first reported a position in CollPlant Biotechnologies in Q3 2018 and has held it in 9 quarters since.
Citadel Advisors's CollPlant Biotechnologies position peaked at $276K in Q2 2021.
15 funds tracked by Wall St. Rank held CollPlant Biotechnologies as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.